ADC Therapeutics SA expected to post a loss of 92 cents a share - Earnings Preview

ADC Therapeutics SA

29/10/2021 14:53

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show a
rise in quarterly revenue when it reports results on November
2. 
* The Epalinges, Vaud-based company is expected to report
revenue of $7.386 million, according to the mean estimate from 6
analysts, based on Refinitiv data.  
​* Refinitiv's mean analyst estimate for ADC Therapeutics SA is
for a loss of 92 cents per share. For the same quarter last
year, the company reported a loss of 77 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for ADC
Therapeutics SA is $44​, about 34.7% above​ its last closing
price of $28.73. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.87       -0.86      -0.96     Missed  -11.6
 Mar. 31 2021  -0.92       -0.90      -0.46     Beat    49.2
 Dec. 31 2020  -0.14       -0.38      -1.05     Missed  -173.9
                                                        ​
 Sep. 30 2020  -0.83       -0.81      -0.77     Beat    4.9
 Jun.          -0.65​      -0.65      -0.73     Missed  -12.3​
 30​ 2020​                                              
 Mar. 31 2020              -0.67                        ​
 This summary was machine generated October 29 at 13:53 GMT.  All
figures in US dollars unless otherwise stated